1 / 9

Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Marke

The new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. For more details : http://goo.gl/jGIpRr

Shubhangi
Download Presentation

Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Marke

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Healthcare Market Research Reports Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023 For More Information Visit : www.aarkstore.com

  2. Summary GlobalDatahas released its new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended. For More Information Visit : www.aarkstore.com

  3. Scope - Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on Lonsurf including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for Lonsurf for the top eight countries from 2013 to 2023.- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China. For More Information Visit : www.aarkstore.com

  4. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of Lonsurf performance- Obtain sales forecast for Lonsurf from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China) For More Information Visit : www.aarkstore.com

  5. Table of Content For More Information Visit : www.aarkstore.com

  6. List Of Tables Table 1: TNM and Staging Classification System for CRC 15Table 2: Symptoms of Colorectal Cancer 16Table 3: Treatment Guidelines for CRC 21Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23Table 6: Leading Treatments for CRC, 2014 32Table 7: Product Profile - Lonsurf 35Table 8: Lonsurf SWOT Analysis, 2014 37Table 9: Global Sales Forecasts ($m) for Lonsurf (TAS-102), 2013-2023 38Table 10: Average Body Weight and Surface Area Across the 8MM 49Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53 For More Information Visit : www.aarkstore.com

  7. Related Reports • Global Telemedicine market report • Global Clinical trial outsourcing report • Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars • 2015 Strategies in the Global Hematology and Flow Cytometry Markets • 2015 Strategies in the European Hematology and Flow Cytometry Markets • 2015 Strategies in the French Hematology and Flow Cytometry Markets • 2015 Strategies in the German Hematology and Flow Cytometry Markets • 2015 Strategies in the Italian Hematology and Flow Cytometry Markets • 2015 Strategies in the Japanese Hematology and Flow Cytometry Markets • 2015 Strategies in the Spanish Hematology and Flow Cytometry Markets For More Information Visit : www.aarkstore.com

  8. Follow Us https://www.facebook.com/aarkstoredotcom https://twitter.com/aarkstore https://plus.google.com/+Aarkstoredotcom/posts https://www.linkedin.com/company/aarkstore-enterprise For More Information Visit : www.aarkstore.com

  9. Contact Us Office Address Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Mail us at contact@aarkstore.com 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 For More Information Visit : www.aarkstore.com

More Related